Kurokawa, T., Iinuma, T., Ebisu, H., Yanagidaira, T., Inaba, Y., Fujiwara, T., . . . Motohashi, S. (2026). A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol. PLoS ONE, 21(2), 1. https://doi.org/10.1371/journal.pone.0342387
Chicago Style (17th ed.) CitationKurokawa, Tomoya, et al. "A Phase I Clinical Trial to Evaluate the Tolerability and Safety of an Allogeneic IPSC-derived INKT Cell and α-GalCer-pulsed Autologous DC Combination Therapy for Patients with Recurrent and Advanced Head and Neck Cancer: A Study Protocol." PLoS ONE 21, no. 2 (2026): 1. https://doi.org/10.1371/journal.pone.0342387.
MLA (9th ed.) CitationKurokawa, Tomoya, et al. "A Phase I Clinical Trial to Evaluate the Tolerability and Safety of an Allogeneic IPSC-derived INKT Cell and α-GalCer-pulsed Autologous DC Combination Therapy for Patients with Recurrent and Advanced Head and Neck Cancer: A Study Protocol." PLoS ONE, vol. 21, no. 2, 2026, p. 1, https://doi.org/10.1371/journal.pone.0342387.
